FDA lagging on nanotechnology

Former FDA deputy commissioner for policy Michael Taylor says the agency lacks the legal authority and financial and staff resources it needs to properly regulate food, drugs, medical devices, dietary supplements, and cosmetics containing nanotechnology materials.

“The pressures of expanding regulatory responsibilities and the increasing cost of doing business, coupled with the failure of Congress and successive administrations to adequately fund even FDA's base operations, are a real threat to FDA's ability to effectively oversee nanotechnology,” Taylor wrote in a Robert Wood Johnson Foundation report.

You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.